Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue
Research and collaboration revenue	$ 1,497	$ 0	$ 2,355	$ 0
Operating Expenses:
Research and development	10,343	9,389	20,489	19,129
General and administrative	4,182	3,273	7,994	6,408
Total operating expenses	14,525	12,662	28,483	25,537
Loss from operations	(13,028)	(12,662)	(26,128)	(25,537)
Other income, net:
Interest income	453	231	1,041	626
Other income (expense)	(12)	(145)	67	(117)
Total other income, net	441	86	1,108	509
Net loss attributable to common stockholders	(12,587)	(12,576)	(25,020)	(25,028)
Comprehensive loss	$ (12,587)	$ (12,576)	$ (25,020)	$ (25,028)
Net loss per share attributable to common stockholders, basic, (in dollars per share)	$ (0.62)	$ (26.00)	$ (1.24)	$ (52.56)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.62)	$ (26.00)	$ (1.24)	$ (52.56)
Weighted-average shares of common stock outstanding, basic (in shares)	20,159,666	483,640	20,155,161	476,167
Weighted-average common shares outstanding, diluted (in shares)	20,159,666	483,640	20,155,161	476,167